株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

低血糖症 : パイプライン分析

Hypoglycemia - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 229785
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
低血糖症 : パイプライン分析 Hypoglycemia - Pipeline Review, H1 2018
出版日: 2018年01月30日 ページ情報: 英文 78 Pages
概要

低血糖症は、血液中のグルコース(ブドウ糖)水準が低下したときに発生します。グルコースは人体のエネルギー源として重要です。低血糖症は突然に発症しますが、少量の血糖値の高い血液を消費することで容易・迅速に制御できます。低血糖の症状としては、空腹感や震え、神経質、冷や汗、めまい/朦朧状態、眠気、混乱、睡眠障害、不安感、脱力感などが挙げられます。睡眠中の低血糖の兆候としては、奇声や悪夢、発汗でパジャマやシーツが湿気ていること、起床時に疲れや苛立ちや困惑を感じていることなどがあります。更に、各種の血糖症治療薬の副作用としても現れます。低血糖症はまた、食事が不規則で量も少なかったり、身体活動が増加したり、アルコール飲料を摂取していたりするといった理由で、インスリン生産量を増加させるための注射や錠剤を利用している人々にも生じます。

当レポートでは、世界各国での低血糖症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

低血糖症の概要

治療薬の開発

  • 低血糖症向けパイプライン製品:概要
  • 低血糖症向けパイプライン製品:比較分析

各企業で開発中の低血糖症治療薬

大学/研究機関で研究中の低血糖症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

低血糖症治療薬:開発中の製品の一覧(企業別)

低血糖症治療薬:研究中の製品の一覧(大学/研究機関別)

低血糖症治療薬の開発に従事している企業

  • Biodel Inc.
  • Eli Lilly and Company
  • Heptares Therapeutics Limited
  • Novartis AG
  • SkyePharma Plc
  • USV Limited
  • XERIS Pharmaceuticals, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S

低血糖症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • 低血糖症向け生物製剤
  • glucagon
  • pasireotide
  • GLP-1 受容体拮抗薬
  • terbutaline sulphate
  • XOMA-358
  • ZP-4207

低血糖症治療薬:最新の薬剤プロファイル

低血糖症治療薬:開発が休止状態の製品

低血糖症治療薬:開発が中止された製品

低血糖症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

目次
Product Code: GMDHC10115IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H1 2018, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 6, 5, 1 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hypoglycemia - Overview
  • Hypoglycemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Hypoglycemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hypoglycemia - Companies Involved in Therapeutics Development
  • Adocia SAS
  • Arecor Ltd
  • Eiger BioPharmaceuticals Inc
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • LATITUDE Pharmaceuticals Inc
  • Novartis AG
  • Rezolute Inc
  • Therakind Ltd
  • USV Pvt Ltd
  • Vectura Group Plc
  • XERIS Pharmaceuticals Inc
  • XOMA Corp
  • Zealand Pharma AS
  • Zucara Therapeutics Inc
  • Hypoglycemia - Drug Profiles
  • dasiglucagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Hypoglycemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • exendin-(9-39) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glucagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glucagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glucagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glucagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glucagon biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3143753 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3185643 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-900018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pasireotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRL-2903 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RZ-358 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • terbutaline sulphate MR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XOMA-129 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hypoglycemia - Dormant Projects
  • Hypoglycemia - Discontinued Products
  • Hypoglycemia - Product Development Milestones
  • Featured News & Press Releases
  • Jan 19, 2018: Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018
  • Dec 07, 2017: Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
  • Nov 20, 2017: Adocia Reports Topline Results of BioChaperone Glucagon Phase 1 Study
  • Sep 21, 2017: JDRF Funds Zucara Therapeutics Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
  • Jul 03, 2017: Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
  • Jun 16, 2017: Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program
  • Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
  • Jun 10, 2017: Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association indicate use for treatment of severe hypoglycemia
  • Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
  • Jun 01, 2017: Adocia Launches First-in-Man Clinical Study of BioChaperone Glucagon BioChaperone Glucagon, a ready-to-use stable aqueous formulat
  • Apr 18, 2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
  • Mar 23, 2017: XOMA provides update on pipeline program XOMA 358 at the 2017 ENDO Meeting
  • Mar 23, 2017: XOMA provides update on pipeline program XOMA 129 at the 2017 ENDO Meeting
  • Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
  • Dec 13, 2016: Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypoglycemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hypoglycemia - Pipeline by Adocia SAS, H1 2018
  • Hypoglycemia - Pipeline by Arecor Ltd, H1 2018
  • Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
  • Hypoglycemia - Pipeline by Eli Lilly and Co, H1 2018
  • Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H1 2018
  • Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2018
  • Hypoglycemia - Pipeline by Novartis AG, H1 2018
  • Hypoglycemia - Pipeline by Rezolute Inc, H1 2018
  • Hypoglycemia - Pipeline by Therakind Ltd, H1 2018
  • Hypoglycemia - Pipeline by USV Pvt Ltd, H1 2018
  • Hypoglycemia - Pipeline by Vectura Group Plc, H1 2018
  • Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2018
  • Hypoglycemia - Pipeline by XOMA Corp, H1 2018
  • Hypoglycemia - Pipeline by Zealand Pharma AS, H1 2018
  • Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1 2018
  • Hypoglycemia - Dormant Projects, H1 2018
  • Hypoglycemia - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Hypoglycemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top